



LJMU Research Online

Saito-Benz, M, Bennington, K, Gray, CL, Murphy, WG, Flanagan, P, Steiner, F, Atkinson, G and Berry, MJ

Effects of Freshly Irradiated vs Irradiated and Stored Red Blood Cell Transfusion on Cerebral Oxygenation in Preterm Infants: A Randomized Clinical Trial.

<http://researchonline.ljmu.ac.uk/id/eprint/16618/>

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Saito-Benz, M, Bennington, K, Gray, CL, Murphy, WG, Flanagan, P, Steiner, F, Atkinson, G and Berry, MJ (2022) Effects of Freshly Irradiated vs Irradiated and Stored Red Blood Cell Transfusion on Cerebral Oxygenation in Preterm Infants: A Randomized Clinical Trial. JAMA Pediatrics. ISSN 2168-6203

LJMU has developed **LJMU Research Online** for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

<http://researchonline.ljmu.ac.uk/>

1 **Title: The effects of freshly-irradiated versus standard red cell**
2 **transfusion on cerebral oxygenation in preterm infants: A**
3 **randomized controlled trial**

4
5 Maria Saito-Benz, MSc,^{1,2} Karen Bennington, MSc,² Clint Gray, PhD,^{1,3} William G. Murphy,
6 MD,^{4,5} Peter Flanagan, BMBS⁴, Frederica Steiner, MBChB,² Greg Atkinson, PhD,⁶ and Mary
7 J. Berry, PhD^{1,2,3}

8
9 **Affiliations:**

10 ¹Department of Pediatrics and Child Health, University of Otago, Wellington, NZ; ²Neonatal
11 Intensive Care Unit, Wellington Regional Hospital, NZ; ³Centre for Translational
12 Physiology, University of Otago, Wellington, NZ; ⁴NZ Blood Service, Wellington Regional
13 Hospital, NZ; ⁵School of Medicine and Medical Science, University College, Dublin, Ireland,
14 ⁶Faculty of Science, Liverpool John Moores University, Liverpool, UK

15
16 **Corresponding author:**

17 Dr. Maria Saito-Benz

18 Address: Department of Pediatrics and Child Health, University of Otago, Wellington, NZ

19 Email: maria.saitobenz@otago.ac.nz

20 Phone: +64 21 631 013

21 Fax: +64 4 385 5898

22
23 **Date of Revision:** 23/11/2021

24

25 **Word counts:**

26 Abstract: words: 350

27 Text: words: 2997 (excluding references & figure legends)

28 Figure/table: 3

29 Reference: 43

30

31 **Short running title: Freshly irradiated versus standard red cell transfusion**

32

33 **KEY POINTS**

34 Question: Are freshly irradiated red blood cells (RBCs) more efficacious in oxygen delivery
35 capacity than irradiated and stored RBCs?

36 Findings: In a proof-of-concept randomized trial transfusion of freshly irradiated RBCs in
37 preterm infants resulted in favorable cerebral oxygenation kinetics compared with transfusion
38 of irradiated and stored RBCs as per the Australia and New Zealand Society of Blood
39 Transfusion Guideline.

40 Meaning: 'On demand' irradiation of RBCs may be considered at institutions where this is
41 practicable to optimize oxygen delivery in the recipient.

42 ABSTRACT

43 **Importance:** Gamma-irradiation of leukoreduced red blood cells (RBCs) prevents
44 transfusion-associated graft-versus-host disease, but it also exacerbates storage lesion
45 formation in RBCs. It is currently unknown whether freshly irradiated RBCs are more
46 efficacious than irradiated and stored RBCs in preterm infants with high transfusion
47 requirement.

48 **Objective:** To determine *in-vivo* efficacy freshly irradiated RBCs (intervention) versus
49 irradiated and stored RBCs (control) in anemic preterm infants.

50 **Design:** In this single-center randomized controlled trial, 64 non-urgent transfusion episodes
51 in 42 preterm infants were studied. Transfusion episodes were randomized to the intervention
52 (RBC irradiated on the day of transfusion, n=32) or control arm (RBCs irradiated and stored
53 as per the ANZSBT guidelines, n=32). Cerebral regional oxygenation (crSO₂) and fractional
54 tissue oxygen extraction (FTOE) were measured by blinded clinicians using Near Infrared
55 Spectroscopy (Sensmart X-100, Nonin) for 3hrs immediately before, immediately after, as
56 well as 1 and 5 days after transfusion. Data were analyzed with a covariate-adjusted linear
57 mixed model, which accounted for multiple transfusions in some infants.

58 **Setting:** Wellington Neonatal Intensive Care Unit, New Zealand

59 **Participants:** Forty-two preterm infants who are <34 weeks gestation at birth and ≥14 days
60 of age

61 **Intervention:** Transfusion of freshly irradiated RBCs

62 **Main Outcomes:** Changes in crSO₂ from immediately before to immediately after the trial
63 transfusion was selected as the pre-specified primary outcome measure.

64 **Results:** Compared to the control group, there was a covariate-adjusted mean increase of
65 2.0% (95%CI: 1.2-2.8%) in crSO₂ and a mean decrease of 0.025 (95%CI: 0.011-0.039) in
66 FTOE immediately after transfusion in infants who received freshly irradiated RBCs. These

67 differences were sustained up to 5 days after transfusion. There were negligible mean
68 changes in crSO₂ or FTOE in infants in the control group at any of the time points.

69 **Conclusion and Relevance:** Transfusion of freshly irradiated RBCs confers a small
70 advantage in cerebral oxygenation that persists for at least 5 days post-transfusion compared
71 to transfusion of irradiated and stored RBC components. ‘On demand’ irradiation of RBC
72 components may be considered at institutions where this is practicable to optimize oxygen
73 delivery in the recipient. Further research is needed to ascertain the clinical significance of
74 this physiological finding.

75 **Trial Registration:** Australia and New Zealand Clinical Trial Registry
76 (ACTRN12617001581358)

77

78

79

80 **KEY WORDS**

81 Transfusion Practices (Neonatal, Pediatrics), Blood Component Preparations, RBC

82 Transfusion

83 INTRODUCTION

84 Preterm infants in Neonatal Intensive Care Units (NICUs), particularly those with extremely
85 low birth weight (<1000g), almost invariably require multiple transfusions of red blood cells
86 before their predicted term 'due dates'.¹⁻³ The vast majority of blood transfusions are for
87 medically stable infants with chronic anemia ('anemia of prematurity; AOP'), with the aim of
88 increasing oxygen delivery to the metabolically active organs during the critical phase of
89 growth and neurodevelopment. Some infants in NICUs may receive up to 200% cumulative
90 replacement of their total circulating volume at birth by means of transfusion.⁴ Therefore,
91 ensuring both the safety and efficacy of this common clinical intervention is of utmost
92 importance.

93

94 In modern transfusion practice, donors and their donated blood products undergo stringent
95 screening and processing to ensure a high standard of safety for recipients. One processing
96 method commonly utilized is gamma-irradiation of leuko-reduced RBCs, which effectively
97 prevents proliferation of viable donor leukocytes thus eliminating the risk of transfusion
98 associated graft-versus-host disease (TA-GvHD) in the recipient.⁵ TA-GvHD is a rare but
99 life-threatening complication of RBC transfusion affecting those with established
100 immunodeficiency. A series of case reports suggests preterm infants with immature immunity
101 may be at risk of TA-GvHD.⁶ In these infants, whether modern pre-storage leukoreduction
102 alone is sufficient in preventing TA-GvHD remains uncertain. A number of institutions
103 worldwide have adopted a universal irradiation policy due to the potential risk of TA-GvHD
104 in those with previously undiagnosed immune dysfunction.⁷ Similarly, irradiation of RBCs
105 given to neonates is routine practice in many NICU settings.

106

107 Recommended dosimetry and shelf life of irradiated RBCs differ between countries and
108 continents. In Europe and Australasia, it is safe to store irradiated RBCs for up to 14 days (up
109 to 28 days in the United States).⁸⁻¹⁰ While these recommendations are primarily based on the
110 acceptable levels of hemolysis and extracellular potassium concentrations in stored units,
111 there is a paucity of literature on the efficacy of irradiated and stored RBCs with regards to
112 oxygen delivery capacity. Limited *in-vivo* evidence to date has highlighted a potentially
113 detrimental effect of storage after irradiation on the ability of RBCs to increase vital organ
114 oxygenation.¹¹ This, in conjunction with *in-vitro* evidence of accelerated storage lesion
115 formation in irradiated and stored RBCs¹²⁻¹⁸, raises a clinically relevant question: does
116 storage following irradiation compromise the primary function of transfused RBCs to
117 improve oxygen delivery in the recipient?

118

119 The aim of the current study is to examine, in a randomized controlled trial (RCT), whether
120 transfusion of freshly irradiated RBC components, compared with transfusion of RBC
121 components irradiated and stored as per the Australia and New Zealand Society of Blood
122 Transfusion (ANZSBT) guidelines¹⁰, resulted in an improved cerebral oxygen delivery in
123 anemic preterm infants. We hypothesized that infants receiving freshly irradiated RBC
124 components would have increased cerebral regional oxygenation (crSO₂) and cerebral
125 fractional tissue oxygen extraction (cFTOE), compared with infants receiving irradiated and
126 stored RBC components.

127

128 MATERIALS AND METHODS

129 Study Design

130 The Near Infrared Spectroscopy for Monitoring Brain Oxygenation: Randomized Controlled
131 Trial of Freshly Irradiation versus Standard Red Cell Transfusion for Anemia of Prematurity

132 (NIMO-Rad) trial was a single-center, randomized, double-blinded, proof-of-concept study
133 comparing transfusion of RBCs irradiated on the day of transfusion ('freshly irradiated') with
134 standard issue RBCs (irradiated and stored for up to 14 days as per the ANZSBT guidelines).
135 The decision to give RBC transfusion to enrolled infants was made solely by the attending
136 clinical team using the high transfusion thresholds adopted from the Premature Infants in
137 Need of Transfusion (PINT) trial.¹⁹ Written informed consent was obtained prospectively
138 from a legal guardian in all cases. The trial protocol was registered on the Australia and New
139 Zealand Clinical Trial Registry (ACTRN12617001581358) prior to enrollment.

140

141 Study Population

142 Preterm infants (<34 weeks gestation at birth) who were ≥ 14 days of age in Wellington
143 NICU, NZ were considered for inclusion in the trial between December 2017 and November
144 2018. Eligible infants were enrolled if written informed consent was given by a legal
145 guardian, and the attending clinician made a decision to give non-urgent RBC transfusion for
146 anemia of prematurity. Infants on invasive respiratory support, undergoing treatment for
147 systemic infections, or those who had hemodynamically significant ductus arteriosus or
148 oedema (due to potential interference with signal acquisition) were excluded. If enrolled
149 infants received multiple RBC transfusions during the trial period, each transfusion episode
150 was randomized independently provided that infants continued to meet the inclusion criteria,
151 no exclusion criteria were identified, and the full 5-day follow up data collection from the
152 previous study transfusion was complete. No participant received an additional transfusion
153 during the 5-day follow up period.

154

155 Randomisation

156 A randomisation sequence was generated with no restriction using a computerized random
157 sequence generator ‘Sealed Envelope’ (www.sealedenvelope.com) by the Biostatistician
158 (GA) based at the Teesside University, UK. It was concealed in a brown envelope and given
159 to the New Zealand Blood Service Hospital Blood Bank prior to enrollment. Once RBC
160 transfusion is prescribed for an enrolled infant by the attending clinician, the study
161 transfusion notification was sent to the Blood Bank service and the trial RBC component was
162 issued according to the randomisation sequence. There was a 3-hr interval between the study
163 transfusion notification and issuing of the study RBC component to allow sufficient time for
164 ‘on-demand’ gamma-irradiation to be performed. Control RBC components were issued with
165 the same time lag to maintain blinding of the clinical team. As RBC irradiation ‘on-demand’
166 was not a standard practice at Wellington Regional Hospital, trial transfusion was only
167 performed Mondays to Saturdays, excluding NZ Public Holidays. If enrolled infants were
168 eligible for multiple study transfusions, each study transfusion episode was randomized
169 chronologically and independently to the intervention or control arms in accordance with the
170 pre-generated randomisation sequence. For the participants who received more than 1 study
171 transfusion, this was taken into account in the linear mixed model in order to avoid
172 pseudoreplication – see statistical analysis section and the supplementary file.

173

174 Red Cell Components provided for transfusion

175 Red cells used for transfusion were produced from whole blood, from known
176 cytomegalovirus antibody negative donors, collected in Citrate-Phosphate Dextrose (CPD)
177 anticoagulant. Plasma was removed, either with or without removal of the buffy coat, and the
178 red cells were re-suspended in an additive solution containing saline, adenine, glucose and
179 mannitol (SAG-M) followed by removal of the leucocytes to a maximum residual white cell
180 content of 5×10^6 per unit. The unit was subsequently divided into 4 satellite packs (‘Pedi-

181 Packs') using a closed system and components stored between 2 and 6 degrees Celsius.
182 Irradiation was performed in accordance with ANZSBT Guidelines.¹⁰ Briefly, red cell
183 components less than 14 days old were subjected to irradiation with a minimum dose
184 achieved in the irradiation field of 25 Gy with no part receiving greater than 50 Gy.

185

186 Blinding

187 Trial RBC components were issued by unblinded Blood Bank personnel who were not part of
188 the clinical or trial team. The expiry date and date of irradiation of the issued RBC
189 components were checked by the NICU Acting Charge Nurse Managers as part of routine
190 transfusion safety protocols, and then masked to maintain blinding of the attending clinicians,
191 cot-side nurses, researchers and parents.

192

193 Intervention and comparator arms

194 All enrolled infants received transfusion of 15ml/kg of the neonatal red cell component over
195 3 hours. Infants in the intervention arm received RBC components irradiated on the day of
196 study transfusion, whilst those in the control arm received RBC components which were
197 batch irradiated and subsequently stored for up to 14 days (as per the ANZSBT guidelines¹⁰).
198 To account for the potentially confounding effects of time since donation and donor
199 characteristics, 4 Pedi-Packs from each adult donor were equally divided between the study
200 arms (2 Pedi-Packs for the intervention and control arms respectively).

201

202 Outcomes

203 As a proof-of-concept study, changes in crSO₂ from immediately before to immediately after
204 trial transfusion was selected as the pre-specified primary outcome measure. Pre-specified

205 secondary outcome measures were cFTOE immediately after transfusion, and crSO₂ and
206 cFTOE at 24hrs and 5 days after transfusion.

207

208 To obtain the physiological outcome measures, spatially-resolved Near Infrared Spectroscopy
209 (Sensmart Model X-100, Nonin, USA) was applied to measure crSO₂ at a sampling rate of
210 0.25Hz for 3hr at the following time points in relation to trial transfusion: immediately
211 before, immediately after, 24hrs and 5 days after. In all cases, a neonatal sensor with light
212 penetration depth of 25mm (EQUANOX 8004CB-NA Advanced, Nonin, USA) was placed
213 on the left forehead avoiding hair and the midline. Peripheral arterial saturation (SpO₂) was
214 recorded concurrently for calculation of cFTOE [(SpO₂ – crSO₂)/SpO₂].

215

216 Sample size estimation

217 Based on data from a previously published observational study¹¹, we estimated *a priori* that
218 a total of 60 transfusion episodes were required to detect a 5% difference in crSO₂ response
219 between the intervention and control groups with a 2-tailed unpaired statistical test, 96%
220 power and *p*-value of .05 (G power 3.1). We based this estimation on an unpaired test
221 between study arms in the absence of information about how many infants would ultimately
222 receive more than one transfusion. We predicted that the presence of paired (within-subjects)
223 cases would ultimately increase, rather than decrease, statistical power when modelled
224 appropriately (see below).

225

226 Statistical analysis

227 Data were analyzed with the SPSS v24 software (IBM, USA). A linear mixed model²⁰ was
228 formulated to quantify mean treatment effects, with associated 95% confidence intervals
229 (95%CI) – Also refer to Data analysis plans in the Supplementary File. Mean treatment

230 effects were *a priori* defined as the covariate-adjusted difference between study groups in
231 terms of the change from baseline at each follow-up timepoint (immediately after, 24 h after
232 and 5 days after transfusion). In order to avoid “pseudoreplication” in the analysis results,²¹
233 this model took into account that a small number of cases in treatment (n= 5) and control
234 (n=3) had more than one transfusion in the trial period. i.e. the design was unbalanced.²⁰
235 Mean treatment effects were covariate-adjusted for baseline (pre) values of the measured
236 outcome as well as gestational age.²² Sensitivity analyses were also undertaken using
237 unadjusted models and models with added covariates of birth weight and pre-transfusion
238 Hb+/-Hct. These covariates were selected on the basis of hypothesized influence on the study
239 outcome variables. Selection of covariance structure for the model was based on the smallest
240 Akaike’s Information Criteria (see supplementary data analysis file). Normal distribution of
241 model residuals was confirmed using a histogram.

242

243 Ethics

244 Prospective approval for the trial was granted by the Human Disability and Ethics Committee
245 of New Zealand (HDEC Ref: 17/CEN/202).

246

247 **RESULTS**

248 A total of 61 infants met inclusion criteria and were considered for non-urgent RBC
249 transfusion by the attending clinical team between 1st December 2017 and 30th November
250 2018. Of these, 42 infants (69%) were enrolled in the trial. Reasons for exclusion of eligible
251 infants are listed in Figure 1. In the enrolled infants, a total of 64 transfusion episodes were
252 randomized as per the trial protocol. No infant received more than 3 trial transfusions. Four
253 transfusion episodes (6%) were lost to follow up (Figure 1) and were excluded from the final
254 analysis. The commonest reason for loss to follow up was development of signs of sepsis

255 needing broad spectrum antibiotics during the 5-day follow up (n=3). No infants had sepsis
256 confirmed by a positive blood culture. These episodes of presumed sepsis were not felt by
257 clinicians to be related to the transfusion of RBC components.

258

259 Characteristics of infants receiving trial transfusions are shown in Table 1. Mean baseline
260 values of gestational age, postnatal age, birth weight, weight at the time of trial transfusion,
261 hemoglobin count, hematocrit ratio, baseline oxygenation kinetics, or age of RBC
262 components since donation were similar between the infants randomized to treatment and
263 control groups (Table 1). Mean (range) age of RBC components since irradiation in the
264 control group was 9 (3 – 14) days.

265

266 The main effect for treatment across all follow-up time-points was 2.1% (95%CI: 1.6-2.7%,
267 $P<0.0005$). The treatment x follow-up time interaction was not statistically significant,
268 indicating relatively consistent mean treatment effects at each follow-up time-point ($P=0.61$).
269 Compared with the control group, infants receiving freshly irradiated RBCs showed a higher
270 covariate-adjusted mean $crSO_2$ immediately after transfusion of 2.0% (95%CI: 1.2 to 2.8%)
271 (Figure 2). Compared with control, in infants receiving freshly irradiated RBCs the post
272 transfusion increase in covariate-adjusted mean $crSO_2$ was sustained at 24hrs (2.4%, 95%CI:
273 1.8 to 3.1%) and 5 days (2.0%, 95%CI: 0.8 to 3.2%). However, there remained negligible
274 changes in $crSO_2$ in infants receiving standard RBCs over the post-treatment follow-up time-
275 points (Figure 2). Mean treatment effects at each follow-up timepoint were similar in
276 magnitude in the unadjusted models, and mean treatment effects at each follow-up time-point
277 were, again, statistically significant (Supplementary file).

278

279 For cFTOE, the main effect for treatment across all follow-up time-points was statistically
280 significant ($P < 0.0005$) and amounted to a reduction of 0.027 (95%CI: 0.017-0.037). The
281 treatment x follow-up time interaction was not statistically significant, indicating relatively
282 consistent mean treatment effects at each follow-up time-point ($P = 0.93$). Compared with the
283 control group, transfusion of freshly irradiated RBCs was associated with a statistically
284 significant covariate-adjusted mean reduction in cFTOE immediately after transfusion of
285 0.025 (95%CI: 0.011 to 0.039) and at 5 days of 0.028, 95%CI: 0.013 to 0.043). In infants
286 receiving standard RBCs there were negligible differences in cFTOE at these timepoints
287 (Figure 2).

288

289 DISCUSSION

290 This is the first RCT to quantify the mean treatment effects of storage on oxygen delivery
291 capacity of gamma-irradiated transfused RBCs. Our study findings indicate that storage of
292 irradiated RBCs within the ANZSBT recommended timeframe (< 14 days), significantly
293 reduces oxygen delivery capacity of transfused RBCs. Furthermore, the observed difference
294 in oxygen kinetics was maintained up to 5 days after transfusion, indicating that, contrary to
295 previous suggestions, function of transfused RBCs does not recover *in-vivo*.^{23, 24}

296

297 To date, clinical trials addressing the efficacy and safety of storage of RBCs have focused
298 almost exclusively on *time since donation*.^{25, 26} However, it is plausible that this timeframe is
299 not the best indicator of structural, biochemical and functional degradation of stored RBCs.²⁷

300 Gamma irradiation is associated with an exponential acceleration in red cell hemolysis with
301 associated increases in extracellular potassium and free-iron, reduced bioactivity of nitric
302 oxide, rheological changes altering the ability of RBCs to pass through the microvasculature,
303 decreased 2,3-DPG, ATP concentrations, reduced pH, and microparticle and microvesicle

304 formation (jointly referred to as ‘storage lesion’ formation).^{16-18, 28-30} Preclinical studies have
305 demonstrated that, unlike other medical interventions, transfused RBCs are not a functionally
306 homogeneous entity, yet there is a paucity of published data on the effect of processing and
307 subsequent storage of RBC components on their *in-vivo* function which must be urgently
308 addressed.

309

310 Preterm infants in NICU represent a unique cohort of medically stable patients with chronic
311 anemia. The causes for anemia of prematurity are multifactorial in nature and include
312 breakdown of fetal hemoglobin following exposure to *ex-utero* ‘oxygen rich’ environment,
313 immature haemopoietic system in the context of rapid postnatal growth, iatrogenic blood
314 loss, nutritional deficiencies and chronic inflammation.^{31, 32} While optimal transfusion
315 thresholds for anemia of prematurity are currently under review, it is generally accepted that
316 these infants require so-called ‘top-up’ transfusions for stable oxygen delivery to vital organs
317 during crucial phases of growth and neurodevelopment.^{33, 34} Whilst commonly adopted
318 transfusion-related trial outcome measures capture important variables such as all-cause
319 mortality and multi-organ dysfunction^{35, 36}, they are less informative on the physiological
320 efficacy of RBC transfusion. We suggest that a more direct measure of *in-vivo* oxygen
321 kinetics, using non-invasive cerebral regional oximetry, provides a valuable insight into
322 function and efficacy of transfused RBCs.

323

324 The current study was conducted at a center practicing high transfusion thresholds adopted
325 from the PINT trial. Previous studies using NIRS have demonstrated that pre-transfusion
326 hemoglobin and hematocrit counts are correlated inversely with the magnitude of changes in
327 cerebral oxygenation following RBC transfusion.³⁷ At high transfusion thresholds in preterm
328 infants small or no changes in cerebral oxygenation were observed following transfusion,

329 indicating that changes in oxygen delivery capacity may be compensated by cardiovascular
330 adaptation at these thresholds.³⁸ Our findings of small increases in cerebral oxygenation, both
331 in the freshly irradiated and the irradiated and stored arms (2.0% and 0.2% respectively), are
332 consistent with previously published data.

333

334 We observed no substantial difference in demographic variables and hematological
335 parameters between the freshly irradiated and the irradiated and stored arms. Additionally,
336 we accounted for the potential confounder of donor characteristics by equally allocating
337 single donor Pedi-Packs between the two study arms. We also analyzed our data with a
338 covariate-adjusted statistical model. Of note, the age of red cell components since donation
339 was shorter for the freshly irradiated group although this difference did not reach statistical
340 significance (10 days vs. 13 days, $p = 0.08$). It is plausible that unblinded Blood Bank staff
341 may have had a natural bias towards selecting red cell components with shorter shelf life for
342 the intervention arm. However, given that the age of red cell components since donation has
343 been shown to have a negligible impact on oxygen kinetics or clinical outcomes, we believe
344 this potential difference would not have altered our trial outcomes. We therefore attribute the
345 difference in oxygen kinetics following trial transfusions in our randomized trial to the
346 practice of storage following gamma-irradiation.

347

348 We acknowledge that our study has a number of limitations. As a physiological study,
349 clinical significance of the small changes in cerebral oxygenation kinetics are not fully
350 understood. Currently, clinical trials are ongoing to determine whether reduction in cerebral
351 hypoxia and hyperoxia burdens could improve long-term outcomes in preterm infants.³⁹⁻⁴¹
352 Mean increase in cerebral oxygenation over the 5 days post-transfusion by about 2.0% was
353 smaller than our anticipated change of 5.0%. It is possible that these changes may

354 preferentially benefit critically ill infants than those with chronic anemia. However, due to
355 logistical challenges ‘on-demand’ irradiation may not be suitable for those who require
356 urgent RBC transfusion. The current study excluded those who required mechanical
357 ventilation or had significant neonatal co-morbidities such as sepsis. In light of TOP and
358 ETTNO trials favoring restrictive transfusion practice in preterm infants^{42, 43}, a larger clinical
359 trial is required to re-examine the effect of irradiation practice on cerebral oxygenation
360 kinetics and clinical outcomes in this vulnerable patient group.

361

362 Nevertheless, our proof-of-concept study highlights new evidence that irradiated and stored
363 RBCs function differently to freshly irradiated RBCs *in-vivo*. Based on the current study
364 findings, we postulate that those who are transfusion dependent for chronic anemia, including
365 preterm infants, may benefit from freshly irradiated RBC components as this may confer
366 superior oxygen delivery to vital organs. ‘On demand’ irradiation of RBC components prior
367 to transfusion is still within the safety framework of current international guidelines and
368 could be considered at institutions where this is practicable. However, long-term clinical
369 implications of our findings warrant further investigation.

370

371 Conclusion

372 In the current study transfusion of freshly irradiated RBCs conferred a small advantage in
373 cerebral oxygenation that persist for at least 5 days post-transfusion compared to transfusion
374 of irradiated and stored RBC components as per the ANZSBT guidelines. ‘On demand’
375 irradiation of RBC components may be considered at institutions where this is practicable,
376 for this practice remains within the safety framework of current international guidelines.

377

378

379 **Acknowledgements**

380 The authors would like to thank the infants and parents who took part in the study, and staff
381 on Wellington Neonatal Intensive Care Unit, NZ.

382

383 **Authorship contributions**

384 All authors have approved the final manuscript as submitted.

385

386 **Access to data statement**

387 MSB and GA had full access to all the data in the study and take responsibility for the
388 integrity of the data and the accuracy of the data analysis.

389

390 **Funding statement**

391 No Funding.

392 References

- 393 1. Guillen, U.; Cummings, J. J.; Bell, E. F.; Hosono, S.; Frantz, A. R.; Maier, R. F.;
394 Whyte, R. K.; Boyle, E.; Vento, M.; Widness, J. A.; Kirpalani, H., International survey of
395 transfusion practices for extremely premature infants. *Semin. Perinatol.* **2012**, *36* (4), 244-7.
- 396 2. Maier, R. F.; Sonntag, J.; Walka, M. M.; Liu, G.; Metze, B. C.; Obladen, M., Changing
397 practices of red blood cell transfusions in infants with birth weights less than 1000 g. *J.*
398 *Pediatr.* **2000**, *136* (2), 220-4.
- 399 3. Bowen, J. R.; Patterson, J. A.; Roberts, C. L.; Isbister, J. P.; Irving, D. O.; Ford, J. B.,
400 Red cell and platelet transfusions in neonates: a population-based study. *Arch. Dis. Child.*
401 *Fetal Neonatal Ed.* **2015**, *100* (5), F411-5.
- 402 4. Widness, J. A., Pathophysiology of Anemia During the Neonatal Period, Including
403 Anemia of Prematurity. *Neoreviews* **2008**, *9* (11), e520.
- 404 5. Olivo, R. A.; da Silva, M. V.; Garcia, F. B.; Soares, S.; Rodrigues Junior, V.; Moraes-
405 Souza, H., Evaluation of the effectiveness of packed red blood cell irradiation by a linear
406 accelerator. *Rev Bras Hematol Hemoter* **2015**, *37* (3), 153-9.
- 407 6. Kopolovic, I.; Ostro, J.; Tsubota, H.; Lin, Y.; Cserti-Gazdewich, C. M.; Messner, H.
408 A.; Keir, A. K.; DenHollander, N.; Dzik, W. S.; Callum, J., A systematic review of transfusion-
409 associated graft-versus-host disease. *Blood* **2015**, *126* (3), 406-14.
- 410 7. Pritchard, A. E.; Shaz, B. H., Survey of Irradiation Practice for the Prevention of
411 Transfusion-Associated Graft-versus-Host Disease. *Arch. Pathol. Lab. Med.* **2016**, *140* (10),
412 1092-7.
- 413 8. European Directorate for the Quality of Medicines & HealthCare, Guide to the
414 preparation, use and quality assurance of blood components. 19th Edition ed.; Council of
415 Europe 2017.
- 416 9. Federal Drug Administration (FDA), Office of Blood Research and Review
417 *Recommendations regarding license amendments and procedures for gamma irradiation of*
418 *blood products (7/22/93) [cited 2017 Sept 18]; 1993.*
- 419 10. Australian and New Zealand Society of Blood Transfusion (ANZSBT), Guidelines for
420 Prevention of Transfusion-associated Graft-versus-Host Disease (TA-GVHD). 2011.
- 421 11. Saito-Benz, M.; Murphy, W. G.; Tzeng, Y. C.; Atkinson, G.; Berry, M. J., Storage after
422 gamma irradiation affects in vivo oxygen delivery capacity of transfused red blood cells in
423 preterm infants. *Transfusion* **2018**, *58* (9), 2108-2112.
- 424 12. Patidar, G. K.; Joshi, A.; Marwaha, N.; Prasad, R.; Malhotra, P.; Sharma, R. R.;
425 Dhawan, H. K., Serial assessment of biochemical changes in irradiated red blood cells.
426 *Transfus. Apher. Sci.* **2014**, *50* (3), 479-87.
- 427 13. Hauck-Dlimi, B.; Schiffer, K.; Eckstein, R.; Strobel, J.; Zimmermann, R., Influence of
428 Irradiation on Leukodepleted Small Unit Red Blood Cell (RBC) Bags for Infant Transfusion in
429 Additive Solution SAG-M. *Clin. Lab.* **2016**, *62* (7), 1295-1301.
- 430 14. Zimmermann, R.; Schoetz, A. M.; Frisch, A.; Hauck, B.; Weiss, D.; Strobel, J.;
431 Eckstein, R., Influence of late irradiation on the in vitro RBC storage variables of
432 leucoreduced RBCs in SAGM additive solution. *Vox Sang.* **2011**, *100* (3), 279-84.
- 433 15. Reverberi, R.; Govoni, M.; Verenini, M., Deformability and viability of irradiated red
434 cells. *Ann. Ist. Super. Sanita* **2007**, *43* (2), 176-85.
- 435 16. Qadri, S. M.; Chen, D.; Schubert, P.; Devine, D. V.; Sheffield, W. P., Early gamma-
436 irradiation and subsequent storage of red cells in SAG-M additive solution potentiate energy

437 imbalance, microvesiculation and susceptibility to stress-induced apoptotic cell death. *Vox*
438 *Sang.* **2017**, *112* (5), 480-483.

439 17. Maia, G. A.; Reno Cde, O.; Medina, J. M.; Silveira, A. B.; Mignaco, J. A.; Atella, G.
440 C.; Cortes, V. F.; Barbosa, L. A.; Santos Hde, L., The effect of gamma radiation on the lipid
441 profile of irradiated red blood cells. *Ann. Hematol.* **2014**, *93* (5), 753-60.

442 18. de Oliveira, G. C.; Maia, G. A.; Cortes, V. F.; Santos Hde, L.; Moreira, L. M.; Barbosa,
443 L. A., The effect of gamma-radiation on the hemoglobin of stored red blood cells: the
444 involvement of oxidative stress in hemoglobin conformation. *Ann. Hematol.* **2013**, *92* (7),
445 899-906.

446 19. Kirpalani, H.; Whyte, R. K.; Andersen, C. C.; Asztalos, E. V.; Heddle, N.; Blajchman,
447 M. A.; Peliowski, A.; Rios, A.; LaCorte, M.; Connelly, R.; Barrington, K.; Roberts, R. S., The
448 Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a
449 restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight
450 infants. *J. Pediatr.* **2006**, *149* (3), 301-307.

451 20. Cnaan, A.; Laird, N. M.; Slasor, P., Using the general linear mixed model to analyse
452 unbalanced repeated measures and longitudinal data. *Stat. Med.* **1997**, *16* (20), 2349-80.

453 21. Lazic, S. E., The problem of pseudoreplication in neuroscientific studies: is it affecting
454 your analysis? *BMC Neurosci.* **2010**, *11*, 5.

455 22. Vickers, A. J.; Altman, D. G., Statistics notes: Analysing controlled trials with baseline
456 and follow up measurements. *BMJ* **2001**, *323* (7321), 1123-4.

457 23. Mintz, P. D.; Anderson, G., Effect of gamma irradiation on the in vivo recovery of
458 stored red blood cells. *Ann. Clin. Lab. Sci.* **1993**, *23* (3), 216-20.

459 24. Heaton, A.; Keegan, T.; Holme, S., In vivo regeneration of red cell 2,3-
460 diphosphoglycerate following transfusion of DPG-depleted AS-1, AS-3 and CPDA-1 red cells.
461 *Br. J. Haematol.* **1989**, *71* (1), 131-6.

462 25. Alexander, P. E.; Barty, R.; Fei, Y.; Vandvik, P. O.; Pai, M.; Siemieniuk, R. A.;
463 Heddle, N. M.; Blumberg, N.; McLeod, S. L.; Liu, J.; Eikelboom, J. W.; Guyatt, G. H.,
464 Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review
465 and meta-analysis. *Blood* **2016**, *127* (4), 400-10.

466 26. Chai-Adisaksotha, C.; Alexander, P. E.; Guyatt, G.; Crowther, M. A.; Heddle, N. M.;
467 Devereaux, P. J.; Ellis, M.; Roxby, D.; Sessler, D. I.; Eikelboom, J. W., Mortality outcomes in
468 patients transfused with fresher versus older red blood cells: a meta-analysis. *Vox Sang.*
469 **2017**, *112* (3), 268-278.

470 27. Yoshida, T.; Prudent, M.; D'Alessandro, A., Red blood cell storage lesion: causes and
471 potential clinical consequences. *Blood Transfus.* **2019**, *17* (1), 27-52.

472 28. D'Alessandro, A.; Liumbruno, G.; Grazzini, G.; Zolla, L., Red blood cell storage: the
473 story so far. *Blood Transfus.* **2010**, *8* (2), 82-8.

474 29. García-Roa, M.; Del Carmen Vicente-Ayuso, M.; Bobes, A. M.; Pedraza, A. C.;
475 González-Fernández, A.; Martín, M. P.; Sáez, I.; Seghatchian, J.; Gutiérrez, L., Red blood cell
476 storage time and transfusion: current practice, concerns and future perspectives. *Blood*
477 *Transfus.* **2017**, *15* (3), 222-231.

478 30. Davey, R. J.; McCoy, N. C.; Yu, M.; Sullivan, J. A.; Spiegel, D. M.; Leitman, S. F., The
479 effect of prestorage irradiation on posttransfusion red cell survival. *Transfusion* **1992**, *32* (6),
480 525-8.

481 31. Aher, S.; Malwatkar, K.; Kadam, S., Neonatal anemia. *Semin. Fetal Neonatal Med.*
482 **2008**, *13* (4), 239-47.

- 483 32. Colombatti, R.; Sainati, L.; Trevisanuto, D., Anemia and transfusion in the neonate.
484 *Semin. Fetal Neonatal Med.* **2016**, *21* (1), 2-9.
- 485 33. Whyte, R.; Kirpalani, H., Low versus high haemoglobin concentration threshold for
486 blood transfusion for preventing morbidity and mortality in very low birth weight infants.
487 *Cochrane Database Syst. Rev.* **2011**, (11), Cd000512.
- 488 34. Andersen, C. C.; Keir, A. K.; Kirpalani, H. M.; Stark, M. J., Anaemia in the Premature
489 Infant and Red Blood Cell Transfusion: New Approaches to an Age-Old Problem. *Current*
490 *Treatment Options in Pediatrics* **2015**, *1* (3), 191-201.
- 491 35. Spinella, P. C.; Tucci, M.; Fergusson, D. A.; Lacroix, J.; Hebert, P. C.; Leteurtre, S.;
492 Schechtman, K. B.; Doctor, A.; Berg, R. A.; Bockelmann, T.; Caro, J. J.; Chiusolo, F.;
493 Clayton, L.; Cholette, J. M.; Guerra, G. G.; Josephson, C. D.; Menon, K.; Muszynski, J. A.;
494 Nellis, M. E.; Sarpal, A.; Schafer, S.; Steiner, M. E.; Turgeon, A. F., Effect of Fresh vs
495 Standard-issue Red Blood Cell Transfusions on Multiple Organ Dysfunction Syndrome in
496 Critically Ill Pediatric Patients: A Randomized Clinical Trial. *JAMA* **2019**, *322* (22), 2179-2190.
- 497 36. Fergusson, D. A.; Hebert, P.; Hogan, D. L.; LeBel, L.; Rouvinez-Bouali, N.; Smyth, J.
498 A.; Sankaran, K.; Tinmouth, A.; Blajchman, M. A.; Kovacs, L.; Lachance, C.; Lee, S.;
499 Walker, C. R.; Hutton, B.; Ducharme, R.; Balchin, K.; Ramsay, T.; Ford, J. C.; Kakadekar, A.;
500 Ramesh, K.; Shapiro, S., Effect of fresh red blood cell transfusions on clinical outcomes in
501 premature, very low-birth-weight infants: the ARIPI randomized trial. *JAMA* **2012**, *308* (14),
502 1443-51.
- 503 37. van Hoften, J. C.; Verhagen, E. A.; Keating, P.; ter Horst, H. J.; Bos, A. F., Cerebral
504 tissue oxygen saturation and extraction in preterm infants before and after blood
505 transfusion. *Arch. Dis. Child. Fetal Neonatal Ed.* **2010**, *95* (5), F352-8.
- 506 38. Jani, P.; Lowe, K.; Hinder, M.; Galea, C.; D'Çruz, D.; Badawi, N.; Tracy, M., Liberal
507 hemoglobin threshold affects cerebral arterial pulsed Doppler and cardiac output, not
508 cerebral tissue oxygenation: a prospective cohort study in anemic preterm infants.
509 *Transfusion* **2019**, *59* (10), 3093-3101.
- 510 39. Hansen, M. L.; Pellicer, A.; Glud, C.; Dempsey, E.; Mintzer, J.; Hyttel-Sorensen, S.;
511 Heuchan, A. M.; Hagmann, C.; Dimitriou, G.; Pichler, G.; Naulaers, G.; Cheng, G.; Vilan, A.;
512 Tkaczyk, J.; Kreutzer, K. B.; Fumagalli, M.; Claris, O.; Fredly, S.; Szczapa, T.; Lange, T.;
513 Jakobsen, J. C.; Greisen, G., Detailed statistical analysis plan for the SafeBoosC III trial: a
514 multinational randomised clinical trial assessing treatment guided by cerebral oxygenation
515 monitoring versus treatment as usual in extremely preterm infants. *Trials* **2019**, *20* (1), 746.
- 516 40. Hyttel-Sorensen, S.; Pellicer, A.; Alderliesten, T.; Austin, T.; van Bel, F.; Benders,
517 M.; Claris, O.; Dempsey, E.; Franz, A. R.; Fumagalli, M.; Glud, C.; Grevstad, B.; Hagmann,
518 C.; Lemmers, P.; van Oeveren, W.; Pichler, G.; Plomgaard, A. M.; Riera, J.; Sanchez, L.;
519 Winkel, P.; Wolf, M.; Greisen, G., Cerebral near infrared spectroscopy oximetry in extremely
520 preterm infants: phase II randomised clinical trial. *BMJ* **2015**, *350*, g7635.
- 521 41. Jani, P., Does Near Infra-Red spectroscopy Targeted Use reduce adverse outcomes in
522 Extremely preterm infants? . ANZCTR12621000778886: 2021.
- 523 42. Kirpalani, H.; Bell, E. F.; Hintz, S. R.; Tan, S.; Schmidt, B.; Chaudhary, A. S.;
524 Johnson, K. J.; Crawford, M. M.; Newman, J. E.; Vohr, B. R.; Carlo, W. A.; D'Angio, C. T.;
525 Kennedy, K. A.; Ohls, R. K.; Poindexter, B. B.; Schibler, K.; Whyte, R. K.; Widness, J. A.;
526 Zupancic, J. A. F.; Wyckoff, M. H.; Truog, W. E.; Walsh, M. C.; Chock, V. Y.; Lupton, A. R.;
527 Sokol, G. M.; Yoder, B. A.; Patel, R. M.; Cotten, C. M.; Carmen, M. F.; Devaskar, U.;
528 Chawla, S.; Seabrook, R.; Higgins, R. D.; Das, A., Higher or Lower Hemoglobin Transfusion
529 Thresholds for Preterm Infants. *N. Engl. J. Med.* **2020**, *383* (27), 2639-2651.

530 43. Franz, A. R.; Engel, C.; Bassler, D.; Rüdiger, M.; Thome, U. H.; Maier, R. F.;
531 Krägeloh-Mann, I.; Kron, M.; Essers, J.; Bühner, C.; Rellensmann, G.; Rossi, R.; Bittrich, H.
532 J.; Roll, C.; Höhn, T.; Ehrhardt, H.; Avenarius, S.; Körner, H. T.; Stein, A.; Buxmann, H.;
533 Vochem, M.; Poets, C. F., Effects of Liberal vs Restrictive Transfusion Thresholds on Survival
534 and Neurocognitive Outcomes in Extremely Low-Birth-Weight Infants: The ETTNO
535 Randomized Clinical Trial. *JAMA* **2020**, *324* (6), 560-570.
536

537

538

539

540

541

542

543

544

545 Figure legends

546

547 **Figure 1: Flow diagram of infants who were considered for inclusion between December**

548 **2017 and November 2018 in Wellington NICU, NZ and reasons for exclusion.**

549

550 **Figure 2: Comparison of freshly irradiated RBCs and control (irradiated and stored)**

551 **RBCs on cerebral regional oxygenation (crSO₂) and cerebral fractional tissue oxygen**

552 **extraction (cFTOE). A sustained increase in crSO₂ and reduction in cFTOE up to 5 days**

553 **after transfusion were observed in infants who received freshly irradiated RBCs. Negligible**

554 **changes in crSO₂ or cFTOE was observed at any of the time points in infants who received**

555 **control RBCs. Data are presented as unadjusted means \pm 95% confidence interval, apart from**

556 **the baseline (zero timepoint) values which were used as a covariate in the statistical model.**

557

558 **Table 1: Participants' characteristics prior to trial transfusion**


Participants' characteristics prior to trial transfusion	Red blood cell groups	
	Freshly irradiated (n=29)	Irradiated & stored (n=31)
Gestational age (weeks + days)	26+3 (24+0 – 31+5)	26+3 (24+0 – 31+5)
Corrected postnatal age (weeks + days)	32+3 (27+3 – 38+2)	32+4 (28+0 – 38+2)
Birth weight (g)	875 (± 237)	923 (± 269)
Current weight (g)	1572 (± 319)	1602 (± 351)
Haematology		
<i>Haemoglobin (g/L)</i>	86 (± 9)	84 (± 8)
<i>Haematocrit (ratio)</i>	0.26 (± 0.03)	0.26 (± 0.03)
Oxygenation kinetics		
<i>Cerebral regional oxygenation (%)</i>	77 (± 3)	78 (± 3)
<i>Peripheral arterial saturation (%)</i>	91 (± 3)	92 (± 3)
<i>Fractional tissue oxygen extraction (ratio)</i>	0.15 (± 0.04)	0.15 (± 0.03)
Age of RBC components		
<i>Since donation (days)</i>	10 (± 4)	13 (± 5)
<i>Since irradiation (days)</i>	0	9 (± 3)

559 Data are presented as mean (± SD) for continuous variables, except for gestational and postnatal age which
560 are presented as mean (range).

561

562

563



Study RBC transfusion

● Intervention □ Control

